Literature DB >> 21625954

HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women.

Anna P Batschauer1, Nathalia G Cruz, Vanessa C Oliveira, Fernanda F Coelho, Izabela R Santos, Michelle T Alves, Ana P Fernandes, Maria G Carvalho, Karina B Gomes.   

Abstract

Genetic factors related to cancer have been extensively studied and several polymorphisms have been associated to breast cancer. The FGFR4, MTHFR, and HFE genes have been associated with neoplastic diseases development. The current report outlines the analysis of the polymorphisms G388A (FGFR4), C677T (MTHFR), C282Y, and H63D (HFE) in Brazilian breast cancer patients. We studied 68 patients with invasive ductal and operable breast carcinoma and 85 women as a control group. The polymorphism frequencies in the breast cancer and control groups were analyzed, but no significant difference was observed by comparing the two groups. The presence of each polymorphism was analyzed according to the clinical features and markers already established as prognostic in the breast cancer group. The C677T, H63D, and G388A polymorphisms were not associated to histological grade, age of diagnosis, expression of HER2 receptor, or estrogen and progesterone receptor. The H63D polymorphism showed a significant association (P = 0.02) with the presence of p53 mutations, and C667T showed association to lymph node involvement (P = 0.05). Lymph node involvement, G388A polymorphism, and histological grade were independently associated to metastasis/death. Our data suggests that the polymorphisms G388A, C677T, and H63D are not useful in breast cancer diagnosis, but they may be significant additional prognostic markers related to breast cancer survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21625954     DOI: 10.1007/s11010-011-0895-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

Review 1.  A renaissance for SRC.

Authors:  Timothy J Yeatman
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan.

Authors:  Yu-Ching Chou; Mei-Hsuan Wu; Jyh-Cherng Yu; Meei-Shyuan Lee; Tsan Yang; Hsiu-Lan Shih; Tsai-Yi Wu; Chien-An Sun
Journal:  Carcinogenesis       Date:  2006-06-15       Impact factor: 4.944

3.  FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

Authors:  F Marmé; W Werft; A Benner; B Burwinkel; P Sinn; C Sohn; P Lichter; M Hahn; A Schneeweiss
Journal:  Ann Oncol       Date:  2010-02-10       Impact factor: 32.976

4.  Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer.

Authors:  Naushad Shaik Mohammad; Rupasree Yedluri; Pavani Addepalli; Suryanarayana Raju Gottumukkala; Raghunadha Rao Digumarti; Vijay Kumar Kutala
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

5.  Dietary folate intake, MTHFR genetic polymorphisms, and the risk of endometrial cancer among Chinese women.

Authors:  Wang-Hong Xu; Martha J Shrubsole; Yong-Bing Xiang; Qiuyin Cai; Gen-ming Zhao; Zhi-xian Ruan; Jia-rong Cheng; Wei Zheng; Xiao Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-02       Impact factor: 4.254

Review 6.  FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.

Authors:  Wei Xu; Yan Li; Xueli Wang; Bo Chen; Yan Wang; Shifeng Liu; Jijun Xu; Weihong Zhao; Jianqing Wu
Journal:  Eur J Cancer       Date:  2010-07-16       Impact factor: 9.162

Review 7.  Environmental and chemical carcinogenesis.

Authors:  Gerald N Wogan; Stephen S Hecht; James S Felton; Allan H Conney; Lawrence A Loeb
Journal:  Semin Cancer Biol       Date:  2004-12       Impact factor: 15.707

8.  Influence of iron on in vivo proliferation and lethality of L1210 cells.

Authors:  R J Bergeron; R R Streiff; G T Elliott
Journal:  J Nutr       Date:  1985-03       Impact factor: 4.798

9.  Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development.

Authors:  R Naidu; Y C Har; N A Taib
Journal:  Oncol Res       Date:  2009       Impact factor: 5.574

10.  HFE H63D mutation frequency shows an increase in Turkish women with breast cancer.

Authors:  Aysen Gunel-Ozcan; Sibel Alyilmaz-Bekmez; Emine Nilufer Guler; Dicle Guc
Journal:  BMC Cancer       Date:  2006-02-19       Impact factor: 4.430

View more
  16 in total

1.  C282Y polymorphism in the HFE gene is associated with risk of breast cancer.

Authors:  Xiaoyan Liu; Chunlei Lv; Xiaorong Luan; Ming Lv
Journal:  Tumour Biol       Date:  2013-05-17

2.  Premenopausal plasma ferritin levels, HFE polymorphisms, and risk of breast cancer in the nurses' health study II.

Authors:  Rebecca E Graff; Eunyoung Cho; Sara Lindström; Peter Kraft; Walter C Willett; A Heather Eliassen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-17       Impact factor: 4.254

3.  Methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in Moroccan women.

Authors:  B Diakite; A Tazzite; K Hamzi; H Jouhadi; S Nadifi
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

4.  Frequency of Human Papillomavirus Genotypes 6, 11, 16, 18 And 31 in Paraffin-Embedded Tissue Samples of Invasive Breast Carcinoma, North- East of Iran.

Authors:  Masoumeh Salehpour; Naser Tayyebi Meibodi; Roghayeh Teimourpour; Adel Ghorani-Azam; Samaneh Sepahi; Sina Rostami; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2015

Review 5.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

6.  A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in breast cancer.

Authors:  Shanliang Zhong; Zhiyuan Chen; Xinnian Yu; Wenjing Li; Jinhai Tang; Jianhua Zhao
Journal:  Mol Biol Rep       Date:  2014-06-29       Impact factor: 2.316

Review 7.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 8.  Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies.

Authors:  Liwa Yu; Jianqiu Chen
Journal:  Diagn Pathol       Date:  2012-12-07       Impact factor: 2.644

Review 9.  Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: Evidence for genetic susceptibility.

Authors:  Pradeep Kumar; Upendra Yadav; Vandana Rai
Journal:  Meta Gene       Date:  2015-10-01

10.  Association of 677 C>T (rs1801133) and 1298 A>C (rs1801131) polymorphisms in the MTHFR gene and breast cancer susceptibility: a meta-analysis based on 57 individual studies.

Authors:  Kai Li; Wusheng Li; Xi Dong
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.